Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic… showed no clear difference in side effects or other adverse events compared with placebo, no intervention or usual care (with or without placebo) (low certainty).

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
Up to 10 days postoperative
RD 0.034 [-0.32, 0.38]
2 studies · 59 participants
Low

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs Placebo mouthwash

Adverse effects requiring withdrawal/discontinuation of study medication · People on continuous VKA treatment undergoing minor oral surgery or dental extractions (eligibility included DOACs and all ages; all four…

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA)… showed no clear difference in side effects or other adverse events requiring withdrawal compared with placebo (placebo solution/mouthwash) (moderate certainty).

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or… 2018 · Cochrane All outcomes
7 days
RD 0.00 [-0.04, 0.04]
2 studies · 128 participants
Moderate

Summary of findings ‐ monotherapy: cavosonstat vs placebo

Adverse events: occurring in at least 10% of cavosonstat treated participants · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Very low

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

Adverse events: most commonly occurring events (occurring in at least 10% of participants) · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 1057 participants
Moderate

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Adverse events ‐ treatment emergent · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor showed no clear difference in adverse events: number of participants with treatment‐emergent… compared with control (ivacaftor alone or tezacaftor plus ivacaftor) (moderate certainty).

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
OR 1.04 [0.53, 2.04]
1 study · 258 participants
Moderate

Summary of findings: ACBT vs PEP mask therapy

Adverse events · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Autogenic drainage vs conventional physiotherapy

Adverse events · adults and children with CF

The review found no eligible studies for this question.

1 finding from 1 review

Autogenic drainage for airway clearance in cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

Adverse events during treatment · adults and children with cystic fibrosis

The review found no eligible studies for this question.

2 findings from 1 review

Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 131 participants
Low

Summary of findings table ‐ Fitusiran prophylaxis vs on‐demand therapy

All adverse events · people with inhibitors

Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).

1 finding from 1 review

Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B 2024 · Cochrane Headline outcomes only
RR 1.6 [1.08, 2.37]
1 study · 60 participants
Moderate

Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis vs on‐demand therapy

All adverse events · people without inhibitors

Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).

1 finding from 1 review

Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B 2024 · Cochrane Headline outcomes only
RR 2.83 [1.47, 5.47]
1 study · 54 participants
Moderate